AR121066A1 - Mutante de fimh, composiciones que lo contienen y uso del mismo - Google Patents

Mutante de fimh, composiciones que lo contienen y uso del mismo

Info

Publication number
AR121066A1
AR121066A1 ARP210100099A ARP210100099A AR121066A1 AR 121066 A1 AR121066 A1 AR 121066A1 AR P210100099 A ARP210100099 A AR P210100099A AR P210100099 A ARP210100099 A AR P210100099A AR 121066 A1 AR121066 A1 AR 121066A1
Authority
AR
Argentina
Prior art keywords
same
compositions containing
fimh
polypeptides
mutant
Prior art date
Application number
ARP210100099A
Other languages
English (en)
Inventor
Jan Grijpstra
Eveline Marleen Weerdenburg
Jeroen Geurtsen
Kellen Cristhina Fae
Louris Jakob Feitsma
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of AR121066A1 publication Critical patent/AR121066A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0266Klebsiella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen polipéptidos que comprenden un dominio lectina de FimH que comprende una mutación de aminoácido que hace que el dominio lectina de FimH esté en la configuración de afinidad baja por la manosa. Se describen además composiciones farmacéuticas que comprenden tales polipéptidos y métodos de estimulación de una respuesta inmunitaria en un sujeto que lo necesita mediante la administración del polipéptido.
ARP210100099A 2020-01-16 2021-01-15 Mutante de fimh, composiciones que lo contienen y uso del mismo AR121066A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20152217 2020-01-16

Publications (1)

Publication Number Publication Date
AR121066A1 true AR121066A1 (es) 2022-04-13

Family

ID=69174406

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100099A AR121066A1 (es) 2020-01-16 2021-01-15 Mutante de fimh, composiciones que lo contienen y uso del mismo

Country Status (13)

Country Link
US (2) US11421003B2 (es)
EP (1) EP4090363A1 (es)
JP (2) JP7485771B2 (es)
KR (1) KR20220128372A (es)
CN (1) CN115038461A (es)
AR (1) AR121066A1 (es)
AU (1) AU2021208493B2 (es)
BR (1) BR112022013720A2 (es)
CA (1) CA3168108A1 (es)
IL (1) IL294445B2 (es)
MX (1) MX2022008830A (es)
TW (1) TW202140521A (es)
WO (1) WO2021144369A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7485771B2 (ja) 2020-01-16 2024-05-16 ヤンセン ファーマシューティカルズ,インコーポレーテッド FimH変異体、その組成物、及びその使用
US20220202923A1 (en) * 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
AR124604A1 (es) 2021-01-12 2023-04-12 Janssen Pharmaceuticals Inc Mutantes de fimh, composiciones con los mismos y uso de los mismos
WO2023111907A1 (en) * 2021-12-17 2023-06-22 Pfizer Inc. Polynucleotide compositions and uses thereof
WO2023227608A1 (en) 2022-05-25 2023-11-30 Glaxosmithkline Biologicals Sa Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドa単糖類縁体
US5370872A (en) 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5593969A (en) 1991-09-03 1997-01-14 Igen Incorporated Lipid-A analogs: monosaccharide and dissaccharide compounds for inhibiting binding of lipid A receptors to lipid A receptors
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
ES2227825T3 (es) 1997-04-01 2005-04-01 Corixa Corporation Composiciones inmunologicas aduvantes acuosas de monofosforil lipido a.
US6500434B1 (en) 1998-04-23 2002-12-31 Medimmune, Inc. Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
JP2003519084A (ja) 1998-10-16 2003-06-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
AU1431101A (en) 1999-10-04 2001-05-10 University Of Maryland Biotechnology Institute Novel adjuvant comprising a lipopolysaccharide antagonist
DE60134499D1 (de) 2000-04-13 2008-07-31 Corixa Corp Immunostimulierende zusammnensetzungen die aminoalkyl glucosaminidephosphat und qs-21 enthalten
EP1299544A2 (en) 2000-07-07 2003-04-09 Medimmune, Inc. Fimh adhesin proteins and methods of use
AU2001218049A1 (en) 2000-08-18 2002-03-04 Med Immune, Inc. Method of administering fimh protein as a vaccine for urinary tract infections
AU2001297896A1 (en) * 2000-12-08 2003-01-02 Medimmune, Inc. Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
CN103285392A (zh) 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
US8753864B2 (en) 2005-05-11 2014-06-17 Eth Zurich Recombinant N-glycosylated proteins from procaryotic cells
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2007765B1 (en) 2006-03-23 2012-06-27 Novartis AG Immunopotentiating compounds
ATE539079T1 (de) 2006-03-23 2012-01-15 Novartis Ag Imidazochinoxalinverbindungen als immunmodulatoren
LT2257307T (lt) 2008-02-20 2018-08-10 Glaxosmithkline Biologicals S.A. Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių
EP2437753B1 (en) 2009-06-05 2016-08-31 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants and vaccine compositions containing them
DK2811981T3 (da) 2012-02-07 2019-06-11 Infectious Disease Res Inst Forbedrede adjuvansformuleringer, der omfatter tlr4-agonister, og fremgangsmåder til anvendelse heraf
PT2996473T (pt) 2013-05-18 2019-11-18 Univ California Composições e métodos para a ativação da sinalização dependente do ''estimulador de genes de interferão''
US9415097B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149522B2 (en) * 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US20150086592A1 (en) 2013-09-25 2015-03-26 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9149521B2 (en) 2013-09-25 2015-10-06 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
AU2015220723C1 (en) 2014-02-24 2018-04-05 Glaxosmithkline Biologicals Sa Novel polysaccharide and uses thereof
JP2018515517A (ja) 2015-05-13 2018-06-14 ユニバーシティ オブ ワシントンUniversity of Washington 尿路病原性大腸菌感染病の処置と予防のための組成物および方法
PL3319633T3 (pl) 2015-07-07 2021-04-19 Janssen Vaccines & Prevention B.V. Szczepionka przeciwko rsv
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
WO2021123360A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
JP7485771B2 (ja) 2020-01-16 2024-05-16 ヤンセン ファーマシューティカルズ,インコーポレーテッド FimH変異体、その組成物、及びその使用
AR124604A1 (es) 2021-01-12 2023-04-12 Janssen Pharmaceuticals Inc Mutantes de fimh, composiciones con los mismos y uso de los mismos

Also Published As

Publication number Publication date
MX2022008830A (es) 2022-10-07
AU2021208493B2 (en) 2023-03-30
TW202140521A (zh) 2021-11-01
KR20220128372A (ko) 2022-09-20
US20210221856A1 (en) 2021-07-22
WO2021144369A1 (en) 2021-07-22
CA3168108A1 (en) 2021-07-22
EP4090363A1 (en) 2022-11-23
IL294445A (en) 2022-09-01
US11421003B2 (en) 2022-08-23
JP2023500749A (ja) 2023-01-10
CN115038461A (zh) 2022-09-09
US12012435B2 (en) 2024-06-18
BR112022013720A2 (pt) 2022-10-11
IL294445B2 (en) 2023-10-01
US20230049056A1 (en) 2023-02-16
AU2021208493A1 (en) 2022-06-30
IL294445B1 (en) 2023-06-01
JP2024045126A (ja) 2024-04-02
JP7485771B2 (ja) 2024-05-16

Similar Documents

Publication Publication Date Title
AR121066A1 (es) Mutante de fimh, composiciones que lo contienen y uso del mismo
CL2019002134A1 (es) Composiciones terapéuticas inmunomoduladoras de arnm que codifican péptidos de activación de mutaciones oncogénicas.
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
AR114445A1 (es) Conjugados de il-15, y sus usos
CR20180027A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer.
BR122020006918B8 (pt) Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MY166228A (en) Compositions comprising mixtures of semifluorinated alkanes
BR112015023105A8 (pt) construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo.
CO7010783A2 (es) Proteína naglu humana recombinante y usos de la misma
BR112015027288A8 (pt) uso de uma dose de imunossupressor, composição de nanocarreadores sintéticos tolerogênicos e kit
IN2014CN04187A (es)
BR112021006598A2 (pt) composição farmacêutica líquida, e, kit
AR104835A1 (es) Composiciones nutricionales que contienen un nivel elevado de inositol y uso de las mismas
AR124604A1 (es) Mutantes de fimh, composiciones con los mismos y uso de los mismos
BR112018017031A2 (pt) formulações de antagonista de il-6 e usos das mesmas
MA45172B1 (fr) Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées
PE20151866A1 (es) Composiciones nutricionales que contienen un componente peptidico con propiedades estimulantes de adiponectina y usos del mismo
AR108631A1 (es) Formulación de neurotoxinas
PE20151978A1 (es) Composiciones nutricionales que contienen un componente peptidico con propiedades antinflamatorias y usos del mismo
CL2022000774A1 (es) Vacunas para vhb y métodos de tratamiento de vhb
CO2020010193A2 (es) Una composición farmacéutica para la anemia
BR112022008497A2 (pt) Derivados terapêuticos da interleucina-22